Silence Therapeutics Plc Stock Price, News & Analysis

Silence Therapeutics presented additional Phase 1 results for divesiran in polycythemia vera (PV) patients at the ASH Annual Meeting. The SANRECO study data showed substantial reduction in phlebotomy frequency and lower hematocrit levels in 19 PV patients. Following treatment, only five phlebotomies were required during the 18-week treatment period, compared to 79 phlebotomies before enrollment.

The company also announced dosing of the first subject in the Phase 2 portion of the SANRECO study. Divesiran demonstrated sustained hematocrit reduction, favorable effects on iron metabolism, and consistent target engagement through increased hepcidin levels. The treatment has been well-tolerated with no dose-limiting toxicities.

Silence Therapeutics (Nasdaq: SLN), a global clinical stage biotechnology company focused on developing precision engineered medicines for disease treatment, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The company will engage in a fireside chat on Wednesday, December 4th at 10:00 a.m. ET. Interested parties can access the live webcast through the Investors section of Silence's website, with an archived replay available after the conference.

Silence Therapeutics (SLN) presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, showing significant results in treating high lipoprotein(a) levels in ASCVD patients. The study demonstrated >80% mean time-averaged placebo-adjusted Lp(a) reductions over 36 weeks, with maximum reductions exceeding 90%. The treatment, administered at various doses and intervals, showed persistent effects up to 60 weeks after initial dosing with no safety concerns. The data was presented at the AHA Scientific Sessions 2024 and published in JAMA, marking the first study to report time-averaged Lp(a) analyses.

Silence Therapeutics (SLN) reported its Q3 2024 financial results with cash position of £129.0 million ($172.7 million) as of September 30, 2024. The company's collaboration revenue decreased to £1.1 million in Q3 2024 from £2.7 million in Q3 2023. R&D expenses increased to £15.3 million from £8.9 million year-over-year, while G&A expenses rose to £5.6 million from £5.0 million. Net loss widened to £27.0 million from £8.2 million in Q3 2023.

The company will present results from the ALPACAR-360 Phase 2 study of zerlasiran at AHA and Phase 1 results of divesiran at ASH in December 2024. Starting January 2025, SLN will be classified as a 'large accelerated filer' by SEC.

Silence Therapeutics (Nasdaq: SLN), a global clinical stage biotechnology company focused on developing precision engineered medicines that silence diseases, has announced its participation in an upcoming fireside chat at the Jefferies London Healthcare Conference. The event is scheduled for Wednesday, November 20th at 2:00 p.m. GMT.

Interested parties can access the live webcast through the Investors section of Silence's website, with an archived replay available after the conference.

Silence Therapeutics, a biotechnology company focused on silencing diseases through precision engineered medicines, has announced its participation in four upcoming investor conferences in September 2024. The company will present overviews at the:

1. Morgan Stanley Global Healthcare Conference on September 5 at 5:35pm ET
2. HC Wainwright Global Investment Conference on September 10 at 11:30am ET
3. Cantor Global Healthcare Conference on September 17 at 10:20am ET
4. Chardan Genetic Medicines Conference on September 30 at 9:00am ET

Live audio webcasts of all presentations will be available on Silence Therapeutics' website, with replays accessible within 48 hours after each event.

Silence Therapeutics (Nasdaq: SLN) reported its Q2 2024 financial results and business highlights. Key points include:

• Positive clinical results for zerlasiran in cardiovascular disease and divesiran in hematological diseases
• $120 million equity raise and collaboration milestones strengthening financial position
• Cash position of £149.6 million ($189.2 million) as of June 30, 2024
• Collaboration revenue of £12.9 million for H1 2024
• Net loss of £17.4 million for H1 2024

The company is advancing its siRNA technology and evaluating partnering opportunities for its mRNAi GOLD™ platform and zerlasiran program.

Silence Therapeutics announced positive results from its Phase 1 SANRECO study of divesiran (SLN124) in polycythemia vera (PV) patients.

The 34-week study evaluated divesiran in 24 patients, with doses administered subcutaneously every 6 weeks for four doses, followed by a 16-week follow-up.

All 8 well-controlled patients (HCT ≤ 45%) required no phlebotomies, while only 2 out of 8 patients with HCT > 45% required one phlebotomy.

Divesiran was well tolerated with no major safety issues. The treatment showed sustained reductions in hematocrit and positive effects on iron metabolism and hepcidin levels.

The company plans to advance divesiran to Phase 2 by the end of the year.

Silence Therapeutics (Nasdaq: SLN) has secured a $2 million payment from Hansoh Pharmaceutical following the achievement of a research milestone in their collaboration. This partnership, initiated in October 2021, focuses on developing siRNAs using Silence's mRNAi GOLD™ platform. Hansoh has already paid Silence $16 million upfront, with potential milestones totaling up to $1.3 billion. Silence holds exclusive rights to two targets globally, except in China, while Hansoh has options in the Greater China region. This latest payment marks the fourth research milestone reached under this agreement.